Sirtex Medical shares are on a tear

Photo: Jack Guez/AFP/Getty Images

Shares in Sirtex Medical jumped after the liver cancer treatment group announced a better than expected lift in earnings.

A short time ago, the shares were up 12.%% to $17.61.

The company said EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) for the six months to December is expected to be to about $34 million, up 16% growth on the same six months last year.

CEO Andrew McLean says he anticipate higher sales in the second half, resulting in full year EBITDA in the range of $75 million to $85 million. This compares to an underlying EBITDA of $61.5 million in the 2017 financial year.

Sirtex makes radioactive spheres to treat liver cancer.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.